ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors

Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in part due to poor patient selection and compensatory...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Escorcia, Freddy E., Houghton, Jacob L., Abdel-Atti, Dalya, Pereira, Patricia R., Cho, Andrew, Gutsche, Nicholas T., Baidoo, Kwamena E., Lewis, Jason S.
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929627/
https://ncbi.nlm.nih.gov/pubmed/31903112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.37098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados